Pierre Beauparlant has more than 19 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization. As Chief Executive Officer, Dr. Beauparlant is responsible for the direction and execution of business strategy for SpecificiT Pharma.
Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities.
Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant is also Chief Business Officer at Therillia and CEO of PreciThera Inc.
Dr. Beauparlant holds a Ph.D. from McGill University.
Michael Dixon has over 18 years’ experience working in an executive role for venture-backed companies.
Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada.
Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon is also president and chief executive officer at Therillia Development Company.
Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.
Marc Lussier has recognized expertise in strategic planning, fundraising, finance, operations and human resources management with more than 15 years of experience in the biopharma sector. He has a proven track record in identifying investment opportunities and actively working with inventors, academic institutions, companies, investors and strategic partners to maximize the value of technologies through public and private financing. Dr. Lussier was responsible along with Dr. Claude Perreault in putting together PCITP(www.pcitp.org). Dr. Lussier holds a Ph.D. in Molecular Biology. He completed a postdoctoral training program with the Department of Biology at McGill University from 1990 to 1995. He was then named Director of the Yeast Genome Lab. In 1998, he founded Mycota Biosciences Inc., a company developing new antifungal agents where he was Director of Scientific Operations until 2001. From 2002 to 2005, he was Vice President of Operations of HemaX Génome Inc, and CEO of Estracure Inc. He subsequently held several concurrent positions as Scientific Director of Procure Prostate Cancer Biobank; part-time Executive Director of Strida Pharma Inc.; Director of Business Development of Émerillon Therapeutics Inc; President and CEO of Florisys Inc.; and Portfolio Director of AgeChem Financial Inc. In 2008, Dr. Lussier became Director of Operations and Business Development of Hôpital Maisonneuve-Rosemont’s Centre of Excellence in Cell Therapy where he oversaw the center’s construction and operationalization.
Frederick Miesowicz brings to SpecificiT his extensive experience in the manufacturing of individualized cellular therapies. He oversees the development of the SpecificiT manufacturing process both at the manual and automated stages. Prior to SpecificT, Dr. Miesowicz was the Chief Operating Officer of Argos Therapeutics, a position which he held for 13 years until 2016. Argos Therapeutics Argos developed immunotherapies by reprograming dendritic cells to target antigens specific to each person’s disease. Prior to this, Dr. Miesowicz was the Vice President of U.S. Operations for Gamida-Cell, a stem cell company. He was Senior Vice President and General Manager of Hybridon Specialty Products. He served as Vice President and General Manager of Cellcor, a subsidiary of Cytogen, Inc., from 1995 to 1998, where he directed all operations related to Cellcor’s cellular immunotherapy programs. He also served as Senior Vice President of Scientific Affairs at Cellcor from 1992 to 1995. Dr. Miesowicz has an extensive background in cellular therapies and medical devices. Prior to joining Cellcor, he managed the U.S. and European SteriCell Division of Terumo Medical Corporation after it was acquired from DuPont, and was with E.I. DuPont de Nemours & Company for over 14 years managing both immunotherapy and immunodiagnostic R&D groups. Dr. Miesowicz holds a B.S. degree in Chemistry from Siena College and received a Ph.D. in Chemistry from Harvard University.